

# **Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/NE2CF6C0F3FEN.html>

Date: April 2018

Pages: 41

Price: US\$ 3,500.00 (Single User License)

ID: NE2CF6C0F3FEN

## **Abstracts**

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2018

### **SUMMARY**

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

The latest report Nitric Oxide Synthase Brain - Pipeline Review, H1 2018, outlays comprehensive information on the Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Nitric oxide synthase 1 or NOS1 is an enzyme encoded by the NOS1 gene. It produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body.

In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Respiratory which include indications Parkinson's Disease, Dyskinesia, Neurodegenerative Diseases, Migraine, Visceral Pain, Bladder Pain, Brain Injury, Hypoxia, Melanoma, Musculoskeletal Pain, Neuroinflammation, Post-Operative Pain and Post-Traumatic Stress Disorder (PTSD).

Furthermore, this report also reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics and enlists all their major and minor projects

The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Overview

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development

Eli Lilly and Co

Neurophoxia BV

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles

2-Iminobiotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-462 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-613 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Products

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Product Development Milestones

Featured News & Press Releases

Aug 31, 2015: Formulation patent granted in US, China, Australia and New Zealand

*Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cyst...*

Jul 31, 2015: Neurophyxia Provides Update on Phase II study of 2-IB  
Sep 30, 2014: Neurophyxia Provides Update on Phase II Clinical Study of 2-Iminobiotin  
Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder  
Feb 29, 2012: Neurophyxia Provides Update on 2-Iminobiotin  
Jun 30, 2011: Neurophyxia Announces Completion of Phase I Study  
Oct 31, 2010: NeurAxon Reports NXN-188 Phase II Data Demonstrates Efficacy In Acute Migraine  
Jun 30, 2010: Neurophyxia Provides Update on Clinical Study of 2-Iminobiotin  
Jan 31, 2010: Neurophyxia Receives Orphan Drug Designation in Europe for 2-IB  
Feb 28, 2009: Neurophyxia Receives Orphan Drug Designation from FDA for 2-Iminobiotin  
Oct 27, 2008: NeurAxon's NXN-188 Names One Of 10 Most Promising Neuroscience Projects  
Sep 30, 2008: Neurophyxia Provides Update on Pre-Clinical Study of 2-Iminobiotin  
Sep 05, 2008: NeurAxon's NXN-188 Demonstrates Pain Relief in Migraine with Aura  
Aug 14, 2007: NeurAxon Announces Positive Phase 1 Trial Data On NXN-188 For Migraine  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Eli Lilly and Co, H1 2018  
Pipeline by Neurophoxia BV, H1 2018  
Dormant Projects, H1 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

### COMPANIES MENTIONED

Eli Lilly and Co

Neurophyxia BV

## I would like to order

Product name: Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/NE2CF6C0F3FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE2CF6C0F3FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970